Zofenopril calcium  (Synonyms: SQ26991)

Zofenopril Calcium (SQ26991) is an orally active angiotensin-converting enzyme (ACE) inhibitor with antioxidant activity and cardioprotective effects. Zofenopril Calcium reduces ROS production and GSH consumption and helps inhibit foam cell formation, thus slowing the progression of atherosclerosis. Zofenopril Calcium prevents cardiac damage caused by chronic Doxorubicin (HY-15142A)^[1][2].

Zofenopril calcium (30-60 μM; 30 min) decreases oxLDL-induced E-selectin, ICAM-1, and VCAM-1 expressiom in human umbilical vein endothelial (HUVEC) monolayers^[1].
Zofenopril calcium (30-60 μM; 30 min) inhibits oxLDL-induced ROS and superoxide formation in HUVECs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Zofenopril calcium (15 mg/kg/day; po via diet for 9 weeks) results a significant decrease in body weight, and prevents the cardiotoxic effects of doxorubicin in rats^[2].
Zofenopril calcium shows no significant antitumor effect in rat A2780 xenograft model^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

448.58

C₂₂H₂₂Ca_0.5NO₄S₂

81938-43-4

Solid

White to off-white

O=C(N(C[C@@H](SC1=CC=CC=C1)C2)[C@@H]2C([O-])=O)[C@H](C)CSC(C3=CC=CC=C3)=O.[0.5Ca2+]

Room temperature in continental US; may vary elsewhere.

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

• [1]. Cominacini L, et al. Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am J Hypertens. 2002 Oct;15(10 Pt 1):891-5.  [Content Brief]

  [2]. Sacco G, et al. Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol. 2001 Feb 23;414(1):71-8.  [Content Brief]